Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
September 24, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers...
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
September 23, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
September 19, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is the first time that any antiviral used in the treatment...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
September 16, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's officeThis approval is backed by a decade of proven safety...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
September 13, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq1,2New subcutaneous (SC)...
Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen
September 10, 2024 10:00 ET
|
F. Hoffmann-La Roche Ltd
Das innovativste Forschungs- und Entwicklungszentrum der Schweiz unterstreicht Roches langfristige Investitionen in den wissenschaftlichen Fortschritt, um den Bedürfnissen der Patienten gerecht zu...
Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
September 10, 2024 10:00 ET
|
F. Hoffmann-La Roche Ltd
Switzerland’s most innovative research and development center underscores Roche’s long-term investment in scientific advancement to meet patient needsThe new center will simplify and increase...
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
September 04, 2024 02:00 ET
|
F. Hoffmann-La Roche Ltd
New Phase II data show vast majority of patients experiencing no relapses or disability progressionFenebrutinib suppressed acute and chronic MRI lesionsFenebrutinib’s safety profile was consistent...
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
August 27, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregiversApproval...
Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
August 20, 2024 08:30 ET
|
F. Hoffmann-La Roche Ltd
Roche is committed to supporting all those working to overcome the mpox outbreak by providing access to high-quality Polymerase Chain Reaction (PCR) testingRoche confirms that its cobas MPXV test, as...